三生国健: 三生国健：关于部分募投项目完成承诺募集资金投入并将节余募集资金永久补充流动资金的公告

Core Viewpoint - Sangfor Biopharmaceuticals (Shanghai) Co., Ltd. has completed the investment commitments for its antibody drug research projects and has decided to permanently supplement its working capital with the remaining funds from these projects [1][6]. Fundraising Overview - The company was approved to publicly issue 61,621,142 shares at a price of RMB 28.18 per share, raising a total of RMB 1,736,483,781.56, with a net amount of RMB 1,634,428,187.64 after deducting fees [1][2]. Investment Projects - The main projects funded include: - New drug research for autoimmune and ophthalmic disease antibodies - Industrialization of innovative antibody drugs and digital factory construction - The total investment for these projects is RMB 335,433.49 million, with RMB 318,275.95 million allocated to the new drug research project and RMB 163,442.82 million to the industrialization project [3][4]. Fund Usage and Surplus - As of August 29, 2025, the company has completed the investment commitments for the aforementioned projects, with a total of RMB 163,733.77 million utilized, resulting in a surplus of RMB 7,029.08 million [4][6]. - The surplus funds will be permanently supplemented into the company's working capital to enhance cash flow and economic efficiency [6]. Approval Process - The board of directors and the supervisory board approved the decision to use the surplus funds, stating it would improve fund utilization efficiency and align with the company's development strategy [6][7]. - The sponsor institution confirmed that the process followed necessary legal procedures and complied with relevant regulations, ensuring no adverse impact on the company's operations [7][8].